Immunovant price to book ratio IMVT

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: 8.0×
7-year median: 7.1×
Against its 7-year history: 59th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.8× to 48.9×
Peer median: 5.6×

Immunovant's price to book ratio is 8.0× as of Oct 23, 2026.

That is above its 7-year median of 7.1×, close to the middle of its last 7 years.

Over that time it ranged from 0.8× in Jun 2022 to 48.9× in Jan 2020.

The median for 10 biotech stocks of a similar size is 5.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.0×	4.7×	12.5×
2025	8.8×	3.6×	10.2×
2024	8.0×	5.8×	24.6×
2023	24.2×	4.5×	24.6×
2022	5.8×	0.8×	5.8×
2021	1.8×	1.6×	11.1×
2020	10.3×	4.7×	48.9×
2019	46.7×	28.3×	46.7×

Against its peers

Companies in Biotechnology nearest Immunovant's size, closest first, today.

Company	Price to book ratio
IMVTImmunovant	8.0×
KRYSKrystal Biotech	6.8×
RGENRepligen	4.7×
TECHBIO-TECHNE	5.4×
HALOHalozyme Therapeutics	99.3×
ADMAAdma Biologics	5.9×
NBIXNeurocrine Biosciences	3.9×
VCELVericel	5.9×
EXELExelixis	8.7×
INCYIncyte	3.7×
UTHRUnited Therapeutics	3.9×
Peer median	5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Immunovant

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.